Natera (NTRA) to Release Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is scheduled to be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Natera to post earnings of ($0.72) per share for the quarter. Natera has set its FY 2024 guidance at EPS.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. The firm had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. On average, analysts expect Natera to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Natera Stock Down 1.0 %

Shares of NASDAQ:NTRA traded down $0.95 during midday trading on Thursday, hitting $93.20. 30,736 shares of the company’s stock were exchanged, compared to its average volume of 1,414,651. Natera has a 12 month low of $36.90 and a 12 month high of $98.82. The company has a market cap of $11.39 billion, a PE ratio of -24.84 and a beta of 1.38. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The stock has a 50 day moving average price of $89.57 and a 200-day moving average price of $68.74.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on NTRA. Stephens restated an “overweight” rating and issued a $78.00 target price on shares of Natera in a report on Tuesday, January 30th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective on the stock in a report on Friday, April 5th. Canaccord Genuity Group increased their target price on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, February 29th. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Raymond James downgraded Natera from a “strong-buy” rating to an “outperform” rating and boosted their target price for the stock from $68.00 to $85.00 in a research note on Tuesday, February 20th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.40.

Insider Buying and Selling

In other Natera news, insider Jonathan Sheena sold 447 shares of Natera stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the transaction, the insider now owns 347,731 shares of the company’s stock, valued at approximately $31,372,290.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Natera news, insider Jonathan Sheena sold 447 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $90.22, for a total value of $40,328.34. Following the transaction, the insider now directly owns 347,731 shares in the company, valued at approximately $31,372,290.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John Fesko sold 929 shares of Natera stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $93.14, for a total value of $86,527.06. Following the sale, the insider now owns 110,748 shares of the company’s stock, valued at approximately $10,315,068.72. The disclosure for this sale can be found here. In the last quarter, insiders have sold 418,913 shares of company stock valued at $34,492,522. Corporate insiders own 9.42% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.